Registered Drug Packs of Antimicrobials and Treatment Guidelines for Prostatitis: Are They in Accordance?
antimicrobial resistance
drug pack
treatment guidelines
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
22 Jun 2022
22 Jun 2022
Historique:
received:
10
05
2022
revised:
14
06
2022
accepted:
20
06
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
The aim of this study was to analyze if registered drug packs of antibiotics are in accordance with national guidelines for prostatitis treatment regard to the amount of drug units.; Methods: Croatian, UK (NICE), Australian, Spanish and Slovenian national guidelines were analyzed in this study. Results: Comparing treatment guidelines with registered drug packs resulted in perfect accordance only for drug packs registered in the UK with the NICE guidelines, where even split-pack dispensing is possible. Interestingly, when comparing drug packs registered in the UK with treatment proposed in the national guidelines of Croatia, Italy, Spain, Australia, USA and Slovenia, they matched almost perfectly. In other investigated countries, registered drug packs' national guidelines' analysis showed mismatch in 25-100% of recommendations (Italy and Slovenia, respectively). Conclusions: Mismatch between registered drug packs that are dispensed to patients and treatment guidelines may result in excess units of antimicrobials that may be misused by the patient in the future, or excess antimicrobials may become unnecessary waste, further promoting antimicrobial resistance. Greater accordance of registered drug packs of antimicrobials with treatment guidelines may lower rates of antimicrobials misuse.
Identifiants
pubmed: 35885685
pii: healthcare10071158
doi: 10.3390/healthcare10071158
pmc: PMC9322485
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Biochem Pharmacol. 2017 Jun 1;133:152-163
pubmed: 27687641
PLoS One. 2019 Mar 28;14(3):e0214572
pubmed: 30921411
Am Fam Physician. 2016 Feb 15;93(4):290-6
pubmed: 26926816
Prim Care. 2010 Sep;37(3):547-63, viii-ix
pubmed: 20705198
Health Care Manag Sci. 2020 Dec;23(4):507-519
pubmed: 33017035
Expert Opin Pharmacother. 2022 Jun;23(9):1091-1101
pubmed: 35574695
Acta Pol Pharm. 2012 Jul-Aug;69(4):571-9
pubmed: 22876597
Microbiol Spectr. 2018 Mar;6(2):
pubmed: 29600770
Aust Fam Physician. 2013 Apr;42(4):216-9
pubmed: 23550248
Int J Antimicrob Agents. 2019 Oct;54(4):478-486
pubmed: 31229671
Front Pharmacol. 2020 Apr 30;11:504
pubmed: 32425775
Microbiol Spectr. 2021 Oct 31;9(2):e0053421
pubmed: 34585972
Helicobacter. 2021 Apr;26(2):e12775
pubmed: 33368852
Am J Infect Control. 2018 Apr;46(4):e25-e29
pubmed: 29592834
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Prostate Cancer Prostatic Dis. 2016 Jun;19(2):132-8
pubmed: 26951713
Aust N Z J Public Health. 2015 Dec;39(6):569-72
pubmed: 26122469
Med Pharm Rep. 2020 Jul;93(3):231-240
pubmed: 32832887
Eur J Clin Microbiol Infect Dis. 2019 Apr;38(4):703-709
pubmed: 30685804
Basic Clin Pharmacol Toxicol. 2018 Mar;122(3):317-321
pubmed: 28889650
Proc Biol Sci. 2018 Mar 14;285(1874):
pubmed: 29540517
Indian J Gastroenterol. 2018 Nov;37(6):550-554
pubmed: 30635887
BJU Int. 2015 Oct;116(4):509-25
pubmed: 25711488
Clin Infect Dis. 2010 Jun 15;50(12):1641-52
pubmed: 20459324
Syst Rev. 2021 Jan 16;10(1):29
pubmed: 33453730
Basic Clin Pharmacol Toxicol. 2020 Mar;126(3):212-225
pubmed: 31520459
Antimicrob Resist Infect Control. 2019 Feb 11;8:30
pubmed: 30792852
Antimicrob Resist Infect Control. 2020 May 8;9(1):60
pubmed: 32384939